SCHEMBL4765736

SCHEMBL4765736

CCCCOC1(c2cccc3ccccc23)CNCC[N]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.36
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SLC6A2 P23975 3/20 0.34
SLC6A3 Q01959 3/20 0.34
SLC6A4 P31645 2/20 0.34
HTR1B P28222 3/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
TP53 P04637 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
TAAR1 Q96RJ0 1/20 0.32
HTR1D P28221 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724348 0.93 SLC6A2 (0.35) SLC6A2SLC6A3SLC6A4HTR1BCNR1
SCHEMBL4724790 0.88 SLC6A3 (0.36) SLC6A2SLC6A3SLC6A4ADRA2AADRA2B
SCHEMBL4721684 0.83 SLC6A3 (0.42) L3MBTL1GAATDP1SLC6A2SLC6A3
SCHEMBL4722937 0.82 SLC6A3 (0.44) L3MBTL1GAATDP1SLC6A2SLC6A3
SCHEMBL4765357 0.81 SLC6A3 (0.39) SLC6A2SLC6A3SLC6A4HTR1BADRA2A
SCHEMBL4723024 0.80 USP2 (0.40) L3MBTL1TDP1NPSR1ALDH1A1CYP2C9
SCHEMBL4722873 0.79 L3MBTL1 (0.38) L3MBTL1GAATDP1SLC6A2SLC6A3
SCHEMBL4720437 0.79 L3MBTL1 (0.36) L3MBTL1GAATDP1SLC6A2SLC6A3
SCHEMBL4722969 0.75 SLC6A3 (0.44) L3MBTL1GAATDP1SLC6A2SLC6A3
SCHEMBL4723127 0.74 SLC6A3 (0.46) GAASLC6A2SLC6A3SLC6A4HTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 L3MBTL1 3954/4885GAA 3876/4885TDP1 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.